EyePoint Pharmaceuticals, Inc. (EYPT) released promising six-month results from its ongoing Phase 2 VERONA clinical trial, which is assessing Duravyu as a treatment option for diabetic macular edema (DME).
The trial included 27 participants who were administered either an intravitreal 1.34 mg or 2.7 mg dose of DURAVYU or were part of the aflibercept control group.
According to the company, the trial successfully met its primary objective, with both the 1.34 mg and 2.7 mg doses of Duravyu showing an extended duration until the need for the first supplemental injection, in comparison to the aflibercept control group.
Most significantly, the 2.7 mg dosage of Duravyu resulted in immediate and significant improvements in both visual acuity and anatomical structure in DME patients, alongside a superior dosing interval and impressive safety profile.
Following these encouraging results, EyePoint plans to launch a Phase 3 non-inferiority program, offering a unique treatment alternative for patients with DME who require effective, safe, and long-lasting treatment solutions.
Additionally, EyePoint intends to consult with the FDA in the second quarter, with the goal of initiating a Phase 3 clinical trial later in 2025.
In pre-market trading, EyePoint's shares have decreased by 21.62%, to $6 on the Nasdaq.
